Pipeline
Our lead drug candidate, CardiolRx™, is being clinically developed for use in rare heart diseases. We are also developing CRD-38, a novel subcutaneously administered drug currently intended for use in heart failure.
| Drug Candidate | Pre-Clinical | Phase I | Phase II | Phase II/III | Phase III |
|---|---|---|---|---|---|
CardiolRx™* |
Recurrent Pericarditis - MAVERIC-2Learn More >Recurrent Pericarditis - MAVERIC-PilotLearn More >Acute Myocarditis - ARCHERLearn More > |
||||
CRD-38 |
Heart FailureLearn More > |
||||
*The Company intends to seek FDA orphan drug and EMA orphan medicine designations for CardiolRx™ for recurrent pericarditis and acute myocarditis.
CardiolRx™
Therapeutic developmentCardiolRx™ (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
CardiolRx™ is pharmaceutically manufactured under cGMP to meet the highest standards for product purity, consistency, and stability. A Phase I safety and pharmacokinetic study of single and multiple ascending doses of CardiolRx™ was completed and demonstrated that CardiolRx™ was safe and generally well tolerated at all dose levels, with no serious adverse events reported. The results supported the Company’s two Investigational New Drug Application authorizations from the United States Food and Drug Administration to conduct two Phase II studies in rare heart diseases: recurrent pericarditis and acute myocarditis.
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis.
CRD-38
Therapeutic developmentCRD-38 is a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.
We are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care.
We are currently developing CRD-38 that is intended to improve the pharmacokinetic profile compared to existing formulations. Subcutaneous administration has the potential to allow for a lower dose of drug to be delivered with less frequent administration, while achieving the same or greater therapeutic effect. Our research collaborators have shown that cannabidiol, when administered subcutaneously, is effective in a pre-clinical model of heart failure. The subcutaneous approach is practical and widely used in human medicine although the formulation requires specific characteristics. We have successfully developed a formulation that meets these required characteristics. Currently, this formulation is undergoing pharmacokinetic testing.
Impact of CardiolRx™ on Recurrent Pericarditis
Multi-center, open-label pilot study to assess the safety and tolerability of CardiolRx™ during the resolution of a pericarditis recurrence, evaluate improvement in objective measures of disease, and assess the feasibility of weaning concomitant background therapy while taking CardiolRx™.
About the Cardiol 100-004 Study (MAvERIC-Pilot)Impact of CardiolRx™ on Myocardial Recovery in Acute Myocarditis
Multi-national, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis.
